25
Participants
Start Date
February 27, 2018
Primary Completion Date
April 27, 2022
Study Completion Date
April 27, 2022
obrindatamab
B7-H3 x CD3 DART protein
retifanlimab
anti-PD-1 antibody
Virginia Cancer Specialists, Fairfax
Sarah Cannon Research Institute, Nashville
START (South Texas Accelerated Research Therapeutics) - Midwest, Grand Rapids
Mary Crowley Cancer Center, Dallas
University of Texas MD Anderson Cancer Center, Houston
University of Southern California, Los Angeles
City of Hope Medical Center, Duarte
Hoag Memorial Hospital Presbyterian, Newport Beach
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Lead Sponsor
MacroGenics
INDUSTRY